-
Here's How Much $100 Invested In Masimo 10 Years Ago Would Be Worth Today
Monday, September 29, 2025 - 6:03pm | 159Read More...Masimo (NASDAQ: MASI) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average annual return of 13.99%. Currently, Masimo has a market capitalization of $7.72 billion. Buying $100 In MASI: If an investor had bought $100 of MASI stock 10 years ago, it...
-
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Monday, September 29, 2025 - 8:06am | 432Read More...U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results. Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate...
-
Here's How Much $1000 Invested In McKesson 20 Years Ago Would Be Worth Today
Thursday, September 25, 2025 - 5:45pm | 159Read More...McKesson (NYSE: MCK) has outperformed the market over the past 20 years by 5.87% on an annualized basis producing an average annual return of 14.69%. Currently, McKesson has a market capitalization of $91.61 billion. Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 20 years ago,...
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Thursday, September 25, 2025 - 8:08am | 428Read More...Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million. Plus Therapeutics (NASDAQ: PSTV) stock moved upwards by 54.0% to $0.62. The company's market cap stands at $40.1 million. Evaxion (...
-
Labcorp Stock Gains From Biopharma Business Amid FX Woe
Monday, October 7, 2024 - 4:08pm | 908Read More...Labcorp Holdings, Inc. (NYSE: LH) or Labcorp benefits from the solid execution of its strategic priorities. Investment in targeted high-growth areas should drive the momentum. The company faces headwinds from macroeconomic uncertainties and growing foreign exchange issues. The stock carries a Zacks...
-
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Monday, June 24, 2024 - 3:30pm | 1231Read More...Bristol Myers Squibb BMY announced that the FDA has approved a label expansion of its oncology drug Krazati (adagrasib). The FDA granted accelerated approval to Krazati, in combination with Erbitux (cetuximab), as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced...
-
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
Thursday, May 23, 2024 - 3:39pm | 1125Read More...The Medical Instruments industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on. This industry is highly...
-
Bristol Myers Updates Action Date for Subcutaneous Opdivo
Thursday, May 23, 2024 - 12:49pm | 686Read More...Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024. The subcutaneous formulation of Opdivo is co-formulated with Halozyme's proprietary recombinant human...
-
Roche Cancer Drug Gets Breakthrough Therapy Designation
Wednesday, May 22, 2024 - 12:15pm | 746Read More...Roche (OTC: RHHBY) obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States. The FDA granted this designation to inavolisib in combination with Ibrance (palbociclib) and Faslodex (fulvestrant) to treat...
-
Merck Ends Keytruda Combo Melanoma Study Due to Futility
Tuesday, May 14, 2024 - 2:33pm | 853Read More...Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma. Data from a...
-
There's Uncertainty Around Apple's Patent Appeal For Watch, Masimo's Royalty Exposure Is Priced In - Analyst Downgrades
Wednesday, January 3, 2024 - 2:30pm | 338Read More...Needham downgraded Masimo Corporation (NASDAQ: MASI), noting that though Apple Inc (NASDAQ: AAPL) royalties are not certain, but are mostly priced into MASI shares. Wednesday, a U.S. appeals court temporarily halted the government commission's import ban on certain...
-
Exceeding Expectations: McKesson Achieves Strong Performance and Rewards Investors
Tuesday, January 2, 2024 - 11:05am | 881Read More...On January 02, 2024, McKesson (NYSE:MCK) will distribute a dividend payout of $0.62 per share, equating to an annualized dividend yield of 0.55%. Shareholders who owned the stock before the ex-dividend date on November 30, 2023 will receive this payout. McKesson Recent Dividend Payouts...
-
Luna's Lunar Leap: Grabs $50M Investment To Fuel Silixa Buyout & More
Thursday, December 21, 2023 - 1:40pm | 379Read More...Luna Innovations Inc (NASDAQ: LUNA) disclosed a strategic investment of $50 million from White Hat Capital Partners. The company will partially use the proceeds to fund the acquisition of Silixa, which was announced today, for $21.5 million in upfront cash consideration and up to an...
-
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
Thursday, December 21, 2023 - 9:54am | 523Read More...The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Tarpeyo was first approved in...
-
Monogram Orthopedics' Surgical Robot Now Reality As Company Delivers First System
Thursday, December 7, 2023 - 9:15am | 965Read More...Robotic surgeries are going mainstream for a good reason: they make it easier for doctors to perform complex surgeries. Monogram Orthopedics Inc. (NASDAQ: MGRM), which aims to revolutionize orthopedic joint replacement surgery with its robotic technology, just got one step closer to achieving that...
